Comparative Effectiveness of Intravitreal Anti-Vascular Endothelial Growth Factor Therapies for Managing Neovascular Age-Related Macular Degeneration: A Meta-Analysis

Frédéric Matonti 1,2,3,4, Jean-François Korobelnik 4,5, Corinne Dot 6, Vincent Gualino 7,8,9,10, Vincent Soler 8,11,12, Sarah Mrejen 13,14, Marie-Noëlle Delyfer 4,5, Stéphanie Baillif 15, Maté Streho 16,17, Pierre Gascon 1,18, Catherine Creuzot-Garcher 19 and Laurent Kodjikian 20,21

Abstract: Intravitreal injections (IVI) of anti-vascular endothelial growth factor (anti-VEGF) have become the standard of care for age-related macular degeneration (AMD). Although most pivotal trials have used monthly injections, alternative strategies that enable the injections to be administered on a more flexible schedule, including pro re nata (PRN) and treat-and-extend (T&E) regimens, are being applied more frequently. This review sought to provide further scientific evidence about the visual outcomes and treatment burden among the currently available anti-VEGF agents and regimens, including aflibercept, ranibizumab, abicipar and brolucizumab. To this end, a systematic review of published randomized studies was conducted from the MEDLINE and EMBASE databases and the Cochrane library, and a meta-analysis was applied to the obtained data using single-means modeling to compare the efficacy and maintenance among the different available treatments and regimens at Years 1 and 2. Quality analysis identified the best-informed data for modeling purposes. Overall, 47 relevant publications were retrieved for the analysis. Superior efficacy, meaning that there were observed improvements in visual acuity (VA) and central retinal thickness (CRT), occurred with monthly versus PRN regimens, yet a higher IVI number was also observed. Conversely, the
T&E regimens displayed similar efficacy to the monthly regimens, but with a reduced IVI number. Aflibercept T&E exhibited similar efficacy to ranibizumab T&E, but with significantly lower IVI numbers at both Year 1 \((p < 0.0001)\) and Year 2 \((p = 0.0011)\). Though all of the regimens resulted in maintained efficacy between Years 1 and 2, the required IVI number varied. The retrieved data did not enable other regimens or newer anti-VEGF agents such as brolucizumab to be compared. In conclusion, the T&E regimens were shown to be the most efficient, optimizing durable effectiveness whilst minimizing the IVI number in newly diagnosed exudative AMD, with aflibercept requiring the lowest IVI number.

**Keywords:** age-related macular degeneration (AMD); aflibercept; comparative therapies; effectiveness; intravitreal anti-vascular endothelial growth factor; meta-analysis; ranibizumab; treat-and-extend; pro re nata regimen

1. **Introduction**

Neovascular age-related macular degeneration (nAMD) is a progressive degenerative disease of the retinal macula that can lead to permanent central vision impairment and blindness [1]. The overall prevalence of the condition in developed countries is estimated to be approximately 8.7% [2]. Risk factors for developing AMD include smoking, a higher body mass index and hypertension, as well as soft drusen and pigment abnormalities within the macula [3,4]. Over the past decade, substantial improvements have been made in the treatment of nAMD, following the introduction of new molecules and treatment regimens. These comprise several agents that are targeted at vascular endothelial growth factor (VEGF), including ranibizumab, bevacizumab, aflibercept, abicipar pegol and brolucizumab.

Indeed, VEGF upregulation, which is assumed to be induced by retinal and choroidal hypoxia, has been shown to drive angiogenesis and increase vascular permeability, which has been observed in nAMD [2]. The visual acuity (VA) gain reported in clinical trials using anti-VEGF agents during the first two years of treatment [5] resulted in a marked upgrade in disease prognosis [6], thereby establishing anti-VEGF agents as the standard of care for this condition [7]. Despite considerable improvements in legal blindness related to nAMD following anti-VEGF introduction, real-world studies have failed to confirm these encouraging data, which is primarily due to under-treatment and a lack of long-term results [2]. A study using the Fight Retinal Blindness observational registry showed that it was possible to achieve good visual outcomes in eyes managed in routine clinical practice with a treat-and-extend (T&E) regimen while also decreasing the treatment burden and number of clinic visits at the same time [8]. Additionally, the monthly intravitreal anti-VEGF injections that are required for the standard of care have been proven to be burdensome for both patients and healthcare systems, often leading to poor treatment adherence in real-life practice [9]. Thus, other regimens that administer anti-VEGF agents at various fixed intervals, such as every 8 or 12 weeks (q8w and q12w, respectively) or as-needed (pro re nata [PRN]), as well as T&E regimens with treatment intervals based on individual disease activity, have been investigated [1,10].

To compare different anti-VEGF agents and regimens, several meta-analyses have been performed [11–14] with the goal of better assisting physicians in their therapeutic decision-making process. Indeed, meta-analyses primarily seek to provide more accurate outcomes and comprehensive conclusions than individual studies through the use of a pool of previously published studies that allow for data comparison [15]. It was in this context that a Cochrane library meta-analysis demonstrated the similar effectiveness and safety of aflibercept versus ranibizumab for managing nAMD patients [12]. Another Cochrane library meta-analysis by Solomon et al. indicated that anti-VEGF agents such as pegaptanib, ranibizumab and bevacizumab had similar effectiveness [11]. A recent network meta-analysis indirectly compared aflibercept and ranibizumab administered...
via T&E regimens and revealed a similar efficacy between the treatment arms, but for aflibercept, this was associated with a significantly reduced number of injections over a two-year period [14]. Nevertheless, it must be stressed that no meta-analysis conducted on nAMD has compared all of the anti-VEGF agents and treatment regimens that are currently available. It must similarly be stressed that 10 to 35% of patients either failed to respond to anti-VEGF agents, referred to as non-responders, or developed resistance to anti-VEGF agents over time, a condition known as tachyphylaxis [16,17]. Given this background, our review primarily sought to provide further scientific evidence regarding the visual outcomes and treatment burden among all of the available anti-VEGF agents and regimens. To this end, we performed a meta-analysis that included data from all of the randomized clinical trials conducted in the nAMD field that were designed to (1) compare the effectiveness of the available treatment regimens at Years 1 and 2, (2) assess the efficacy maintenance of the various regimens over time and (3) compare the effectiveness of various anti-VEGF agents using the same treatment regimen at Years 1 and 2.

2. Methods
2.1. Selection of Studies
A systematic literature review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and the Cochrane Collaboration statement [18,19]. We looked for studies using a sensitive search strategy pertaining to anti-VEGF agents used in AMD management in the PubMed/Medline®, Embase® (access via Ovid platform) and Cochrane CENTRAL databases from the earliest available time up to 16 March 2020. Moreover, studies from ClinicalTrial.gov (accessed on 15 March 2022) with detailed results that had not been published elsewhere were retrieved, as well. The individual search terms applied for the searches are listed in Table 1. The selection of search terms was based on a two-expert consultation. Studies from PubMed were limited to “clinical trials” and “human” studies, with animal and basic science studies being excluded from the analysis, whereas studies from ClinicalTrials.gov were limited to those that were either “terminated” or “completed”. After the database search, two of the authors of this review independently selected articles, and selection was followed by a double-check and validation process. The manual selection process for eligible publications comprised a review of the titles and abstracts; studies that did not match the previously established criteria were excluded. Next, the abstracts and full texts of the retrieved publications were read by the authors in full, thereby confirming their eligibility. The selected publications reported results of prospective, randomized controlled studies related to exudative nAMD and its synonyms and acronyms. The Cochrane risk of bias tool was applied to further assess the quality of the included studies. All of the selected studies had at least one treatment arm involving first-line treatment, thus involving treatment-naïve patients undergoing first-line treatment with one of the following agents: aflibercept 2 mg, ranibizumab 0.5 mg, bevacizumab 1.25 mg, brolucizumab 6 mg or abicipar pegol 2 mg. Phase 1 studies, in addition to subgroup or post hoc analyses, were excluded. Moreover, to meet the eligibility criteria, these studies needed to include primary or secondary outcome measures assessing the best-corrected visual acuity (BCVA) and BCVA at ≥12 months after the baseline. In contrast, studies involving previously treated patients and those with a follow-up duration of <12 months or >24 months without any available intermediate data were not considered. Based on these criteria, a total of 69 studies were retrieved.
Table 1. Search terms used in the systematic literature review.

| Queried Database                  | Filter                                                                 | No. Studies | Comment                                                                 |
|-----------------------------------|------------------------------------------------------------------------|-------------|-------------------------------------------------------------------------|
| PubMed                            | (visual acuity) AND (randomised OR randomized) AND (wet age-related macular degeneration [Title/Abstract]) OR (exudative age-related macular degeneration [Title/Abstract]) OR (neovascular age-related macular degeneration [Title/Abstract]) OR (wet AMD [Title/Abstract]) OR (exudative AMD [Title/Abstract]) OR (neovascular AMD [Title/Abstract]) OR (wAMD [Title/Abstract]) OR (eAMD [Title/Abstract]) OR (nAMD [Title/Abstract]) OR (wAMD [Title/Abstract]) OR (exudative AMD [Title/Abstract]) OR (neovascular AMD [Title/Abstract]) OR (wAMD [Title/Abstract]) OR (eAMD [Title/Abstract]) OR (nAMD [Title/Abstract]) AND (aflibercept [Title/Abstract]) OR (ranibizumab [Title/Abstract]) OR (bevacizumab [Title/Abstract]) OR (brolucizumab [Title/Abstract]) OR (abicipar [Title/Abstract]) OR (brolucizumab [Title/Abstract]) Filters: Clinical Trial; Humans | 207 | No filter was applied for the doses, times at which visual acuity was assessed or the nature of the prospective design, and these aspects were treated manually |
| Cochrane Central Register for Controlled Trials * | “age related macular degeneration” in Title Abstract Keyword AND “Aflibercept” OR “Ranibizumab” OR “Bevacizumab” OR “Brolucizumab” OR “Abicipar” in Title Abstract Keyword AND randomized in Title Abstract Keyword AND visual acuity in Title Abstract Keyword—in Trials (Word variations were searched) | 229 | The selection process was as carried out on studies found in Embase but not referenced in PubMed. No filter was applied for the doses, times at which visual acuity was assessed or prospective nature, and these aspects were treated manually |
| ClinicTrials.gov                  | “age related macular degeneration” in Title Abstract Keyword AND “Aflibercept” OR “Ranibizumab” OR “Bevacizumab” OR “Brolucizumab” OR “Abicipar” in Title Abstract Keyword AND randomized in Title Abstract Keyword AND visual acuity in Title Abstract Keyword—in Trials (Word variations were searched) Filters: Terminated OR Completed | 68 | Of these 68 trials, 60 were retrieved from PubMed or Embase. No filter was applied for the doses, times at which visual acuity was assessed or the nature of the prospective design, and these aspects were treated manually |

* Only studies referenced in Embase were selected.

2.2. Data Extraction and Outcome Analyses

Relevant data were manually extracted from each selected publication and were transcribed into an Excel sheet, and these data were subsequently verified by a second reader. The following data were included: population-related criteria, such as the number of patients, patients lost to follow-up and demographic data; choroidal neovascularization (CNV) features such as the type and presence of polypoidal choroidal vasculopathy (PCV); treatment criteria, including the therapeutic regimen, proportion of patients receiving treatment every 4, 6, 8, 10, 12 or 16 weeks, proportion of patients receiving treatment every ≥8, 12 or 16 weeks, average treatment interval at month 12 or 24 and the IVI number; functional criteria, including the BCVA at the baseline and at month 12 or 24, mean gain in BCVA from the baseline or from randomization depending on the trial design, proportion of patients with BCVA gain ≥15 letters, proportion of patients with BCVA gain ≥5 letters
and proportion of patients with VA loss ≥15 letters; anatomical features such as central retinal thickness (CRT) at the baseline and at month 12 or 24, mean reduction in CRT and the intra-retinal fluid (IRF) or subretinal fluid (SRF) at the baseline and at month 12 or 24.

To define the follow-up duration, the outcomes that were assessed at 52 ± 4 weeks were considered one-year data, and those assessed at 104 weeks ± 4 weeks were considered two-year data; study arms with other follow-up durations were excluded from the meta-analysis. For better homogeneity within each protocol type and to ensure relevant comparisons, only study arms with an induction phase consisting of the administration of at least two monthly loading doses were considered. In the event of a change in the treatment/regimen during the second year, two-year data were excluded from the analysis. For every six-weekly (q6w) dosing regimen, study arms that were in the induction phase or that took place throughout the treatment period were excluded, meaning loading dose and maintenance treatment regimens could be distinguished during the second year. When the studies were selected, it is important to note that bevacizumab was being used off-label for the treatment of wAMD in many European countries, and the question of whether the use of this off-label therapy was responsible or not went unanswered, with a benefit–risk assessment under investigation [20]. Therefore, study arms involving the off-label use of bevacizumab alone were not retained for the final analysis. Of note, the European Medicines Agency (EMEA) recently documented that it did not approve a marketing authorization for a bevacizumab-based drug due to the lack of appropriate safety and efficacy that had been demonstrated and concerns about the risks outweighing the benefits. Instead, a temporary-use authorization (TUA) was granted [21].

2.3. Data Synthesis and Analysis

Studies were assessed for clinical and methodological heterogeneity and for the risk of bias, as well as to determine their suitability for inclusion in the model. Single-means modeling based on fixed- and random-effect models and heterogeneity tests were applied to compare the anti-VEGF regimens, as well as agents within the same regimen. Next, “2 to 2” modeling was applied to further refine the comparisons of various anti-VEGF regimens and agents, aiming to retain the most relevant and robust data. A meta-analysis of the data was conducted to compare the study arms. All of the study arms with means, standard deviations and counts were entered into the model to attain significant statistical power. Intra-study comparisons between randomized study arms were not carried out. Visual outcome data were analyzed following conversion into ETDRS letters if not already available, similar to in [22].

Data quality analysis was conducted to identify the best-informed data at Years 1 and 2, as well as the best-informed clinical outcomes at Year 1, for inclusion in the model. For illustration, the age criterion was very well-informed, whereas other criteria such as the number of visits were poorly informed, meaning that the latter were unable to provide statistical power. The best-informed data at Years 1 and 2 were comparisons of monthly, T&E and PRN regimens, as well as comparisons of aflibercept and ranibizumab, with 75% of the eye of concern being included. Moreover, the best-informed clinical outcomes at Year 1 were improvements in BCVA, reductions in CRT and the IVI number. All of the statistical analyses were conducted using R statistical software version 3.6.0 (R Core Team 224 2019).

2.4. Compliance with Ethical Guidelines

This meta-analysis was a secondary statistical analysis that combined data collected by eligible clinical trials. The data sources primarily included data from the public domain, and one clinical trial contained limited patient data. All of the clinical data were anonymized before they were entered into the model, with the analysts having no access to any personal information that would enable them to identify individual patients. For this reason, ethical committee approval was not required for this meta-analysis.
3. Results

3.1. Included Studies

The literature searches across all of the databases and the references of systemic reviews returned a total of 5389 references. After further filtering, a total of 207 publications were retrieved from PubMed, and 330 were retrieved from Embase. The removal of 187 duplicates yielded 350 unique results. After further evaluation, 68 publications and one additional completed clinical trial with relevant results identified from ClinicalTrials.gov were selected. Following the application of previously mentioned inclusion and exclusion criteria to these 69 reports, 47 were retained for the final analysis (Figure 1), and the details of these 47 reports are provided in Table 2. Overall, the included publications provided one-year data from 78 treatment arms (12,689 eyes) and two-year data from 35 treatment arms (8560 eyes).

Figure 1. Flow chart of included reports.

Table 2. Included reports.

| Reference                        | Study Name | Phase | N   | Treatment Arm(s) of Interest | Regimen Comparisons of Interest | Outcomes of Interest         |
|----------------------------------|------------|-------|-----|------------------------------|---------------------------------|------------------------------|
| Dugel PU et al. 2020b [23]       | HAWK,      | III   | 1459| Aflibercept 2 mg q8w vs. brolucizumab 3 or 6 mg q12/8w | q8 vs. q12/q8                  | • BCVA                        |
|                                  | HARRIER    |       |     |                              |                                 | • CRT                         |
|                                  | (Dugel, Koh et al. 2020) |       |     |                              |                                 | • IVI (for brolucizumab only) |
| Kertes PJ et al. 2020 [24]       | CANTREAT   | III   | 466 | Ranibizumab                  | Monthly vs. T&E                 | • BCVA                        |
|                                  | (Kertes, Galic et al. 2020) |       |     |                              |                                 | • CRT                         |
|                                  |            |       |     |                              |                                 | • IVI                         |
Table 2. Cont.

| Reference | Study Name | Phase | N  | Treatment Arm(s) of Interest | Regimen Comparisons of Interest | Outcomes of Interest |
|-----------|------------|-------|----|------------------------------|---------------------------------|---------------------|
| Ohji M et al. 2020 [14] (Ohji, Takahashi et al. 2020) | ALTAIR | IV    | 458 | Aflibercept                  | T&E (2w or 4w intervals)         | BCVA, CRT, IVI      |
| Staurenghi G et al. 2020 [25] (Staurenghi, Garweg et al. 2020) | OCTAVE | III   | 305 | Ranibizumab                  | PRN (VA guided vs. VA and/or OCT guided) | BCVA, CRT, IVI |
| Gillies MC et al. 2019 [26] (Gillies, Hunyor et al. 2019) | RVAL   | IV    | 559 | Ranibizumab 0.5 mg vs. aflibercept 2.0 mg | T&E | BCVA, CRT, IVI |
| Guymer RH et al. 2019 [27] (Guymer, Markey et al. 2019) | FLUID   | IV    | 690 | Ranibizumab 0.5 mg           | T&E (intensive vs. relaxed retinal fluid treatment regimen) | BCVA, CRT, IVI |
| Kertes PJ et al. 2019 [28] (Kertes, Galic et al. 2019) | CANTREAT | IV   | 526 | Ranibizumab                  | Monthly vs. T&E                | BCVA, IVI          |
| Mitchell P et al. 2019 [29] (Mitchell, Souied et al. 2019) | ARIES  | IV    | 271 | Aflibercept                  | q8w vs. T&E                   | BCVA, CRT, IVI     |
| Nunes RP et al. 2019 [30] (Nunes, Hirai et al. 2019) | –    | III     | 30 | Ranibizumab vs. bevacizumab   | PRN                            | BCVA, CRT, IVI     |
| Semeraro F et al. 2019 [31] (Semeraro, Gambicordi et al. 2019) | –    | Pilot   | 20 | Aflibercept                  | PRN                            | BCVA, CRT, IVI     |
| Wykoff CC et al. 2018 [32] (Wykoff, Ou et al. 2018) | TREX-AMD | III   | 60  | Ranibizumab                  | Monthly vs. T&E               | BCVA, CRT, IVI     |
| Russo A et al. 2018 [33] (Russo, Scaroni et al. 2018) | –    | Pilot   | 29 | Ranibizumab                  | PRN                            | BCVA, CRT, IVI     |
| Silva R et al. 2018 [34] (Silva, Berta et al. 2018) | TREND   | III    | 650 | Ranibizumab                  | Monthly vs. T&E               | BCVA, CRT, IVI     |
| Dugel PU et al. 2017 [35] (Dugel, Jaffe et al. 2017) | OSPREY | II    | 99  | Aflibercept 2 mg vs. brolucizumab 6 mg | q8w or q8w/q12w | BCVA, CRT, IVI |
| Feltgen N et al. 2017 [36] (Feltgen, Bertelmann et al. 2017) | RABIMO  | IV    | 40  | Ranibizumab 0.5 mg           | q8w vs. PRN                   | BCVA, CRT, IVI     |
| Gallemore RP et al. 2017 [37] (Gallemore, Wallsh et al. 2017) | RADICAL | II    | 82  | Ranibizumab 0.5 mg           |                                | BCVA, CRT, IVI     |
| Li K et al. 2017 [38] (Li, Chen et al. 2017) | SIGHT   | III    | 228 | Aflibercept                  | q8w                            | BCVA, IVI          |
| Mori R et al. 2017 [39] (Mori, Tanaka et al. 2017) | –     | IV    | 58  | Aflibercept                  | q8w vs. PRN                   | BCVA, CRT, IVI     |
Table 2. Cont.

| Reference                         | Study Name     | Phase | N  | Treatment Arm(s) of Interest  | Regimen Comparisons of Interest | Outcomes of Interest |
|-----------------------------------|----------------|-------|----|-----------------------------|--------------------------------|----------------------|
| Weingessel B et al. 2016 [40]     | –              | NR    | 16 | Ranibizumab PRN             |                                | BCVA, CRT, IVI       |
| Berg K et al. 2016 [41]           | LUCAS          | NR    | 339| Ranibizumab 0.5 mg vs. bevacizumab 1.25 mg | T&E                             | BCVA, CRT, IVI       |
| Berg K et al. 2015 [42]           | LUCAS          | NR    | 371| Ranibizumab 0.5 mg vs. bevacizumab 1.25 mg | T&E                             | BCVA, CRT, IVI       |
| Eldem BM et al. 2015 [43]         | SALUTE         | IV    | 77 | Ranibizumab 0.5 mg PRN      |                                | BCVA, CRT, IVI       |
| Semeraro F et al. [44]            | –              | Pilot | 25 | Ranibizumab PRN             |                                | BCVA, CRT, IVI       |
| Wykoff CC et al. 2015 [45]        | TREX-AMD       | IIIb  | 60 | Ranibizumab q4w vs. T&E     |                                | BCVA, CRT, IVI       |
| Ho AC et al. 2014 [46]            | HARBOR         | III   | 1100| Ranibizumab q4w vs. PRN     |                                | BCVA, CRT, IVI       |
| Dugel PU et al. 2013 [47]         | CABERNET       | III   | 155| Ranibizumab 0.5 mg PRN      |                                | BCVA, CRT, IVI (1-year data only) |
| Kodjikian L et al. 2013 [48]      | GEFAL          | III   | 374| Ranibizumab vs. bevacizumab PRN |                                | BCVA, CRT, IVI       |
| Krebs I et al. 2013a [49]         | –              | NR    | 24 | Ranibizumab PRN             |                                | BCVA, CRT, IVI       |
| Krebs I et al. 2013b [50]         | MANTA          | III   | 317| Ranibizumab vs. bevacizumab Q4w |                                | BCVA, CRT, IVI       |
| Ranchod TM et al. 2013 [51]       | LUCE-DEX       | II    | 20 | Ranibizumab PRN             |                                | BCVA, CRT, IVI       |
| Heier JS et al. 2012 [52]         | VIEW 1, VIEW 2 | III   | 1815| Aflibercept vs. ranibizumab q4w vs. q8w |                                | BCVA, CRT             |
| Kaiser PK et al. 2012 [53]        | DENALI         | IIIb  | 112| Ranibizumab PRN             |                                | CRT, IVI             |
| Larsen M et al. 2012 [54]         | MONT-BLANC     | II    | 133| Ranibizumab PRN             |                                | BCVA, CRT, IVI       |
| Soderberg AC et al. 2012 [55]     | –              | III   | 44 | Ranibizumab PRN             |                                | BCVA, CRT, IVI       |
Table 2. Cont.

| Reference                        | Study Name                          | Phase | N  | Treatment Arm(s) of Interest | Regimen Comparisons of Interest | Outcomes of Interest |
|----------------------------------|-------------------------------------|-------|----|------------------------------|---------------------------------|---------------------|
| Williams PD et al. 2012 [56]     |                                     | –     | 27 | Ranibizumab                  | PRN                             | BCVA, CRT, IVI      |
| (Williams, Callanan et al. 2012) |                                     |       |    |                              |                                 |                     |
| Holz FG et al. 2011 [57]         | SUSTAIN III                         | III   | 513| Ranibizumab                  | PRN                             | BCVA, CRT, IVI      |
| (Holz, Amoaku et al. 2011)       |                                     |       |    |                              |                                 |                     |
| Martin DF et al. 2012 [58]       | CATT III                            | 778   |    | Ranibizumab vs. bevacizumab  | q4w vs. PRN                     | BCVA, CRT, IVI      |
| (Comparison of Age-related Macular Degeneration Treatments Trials Research, Martin et al. 2012) |       |       |    |                              |                                 |                     |
| Schmidt-Erfurth U et al. 2011   | EXCITE IIb                          | 88    |    | Ranibizumab                  | q12w                            | BCVA, CRT, IVI      |
| [59] (Schmidt-Erfurth, Eldem et al. 2011) |       |       |    |                              |                                 |                     |
| Vallance JH et al. 2010 [60]     | HAWK/HARRIER III                    | 1459  |    | Aflibercept vs. brolucizumab | q8w vs. q8w/q12w                | BCVA, CRT, IVI      |
| (Vallance, Johnson et al. 2010)  |                                     |       |    |                              |                                 |                     |
| Dugel PU et al. 2020c [23]       |                                    |       |    |                              |                                 |                     |
| Heier JS et al. 2011 [61]        | CLEAR-IT II                         | 31    |    | Aflibercept                  | PRN                             | BCVA, CRT, IVI      |
| Kunimoto D et al. 2020 [62]      | CEDAR/SEQUOIA III                   | 1648  |    | Ranibizumab vs. abicipar     | q4w vs. q8w vs. q12w            | BCVA, CRT, IVI      |
| Khurana RN et al. [63]           | CEDAR/SEQUOIA III                   | 1411  |    | Ranibizumab vs. abicipar     | q4w vs. q8w vs. q12w            | BCVA, CRT, IVI      |
| The CATT Research Group, 2011    | CATT NR                             | 1185  |    | Ranibizumab vs. bevacizumab  | q4w vs. PRN                     | BCVA, CRT, IVI      |
| Taipale C et al. 2020 [65]       |                                    |       |    |                              |                                 |                     |
| Mitchell P et al. 2019 [29]      | ARIES IV                            | 135   |    | Aflibercept                  | T&E                             | BCVA, CRT, IVI      |
| Li K et al. 2016 [66] (Li, Zhu et al. 2016) | DRAGON IV                         | 499   |    | Ranibizumab                  | q4w vs. PRN                     | BCVA, CRT, IVI      |

Subgroup of treatment-naive patients; Selected study arm only (i.e., ranibizumab 0.5 mg q4w after ranibizumab induction). Abbreviations: NR, not reported; PRN, as-needed regimen; q4w, every 4 weeks; q8w, every 8 weeks; q12w, every 12 weeks; T&E, treat-and-extend regimen; BCVA, best-corrected visual acuity; CRT, central retinal thickness; IVT, intravitreal injections.

3.2. Evaluated Treatments

Among the studies included in the analysis, the following anti-VEGF agents were evaluated: ranibizumab 0.5 mg (74% of studies), aflibercept 2 mg (20% of studies) and brolucizumab 6 mg (4% of studies), whereas none of the included studies evaluated abicipar pegol 2 mg. Three studies using bevacizumab 1.25 mg alone were not retained.
For seven other studies using bevacizumab along with a comparative arm, the latter arm was considered for analysis, whereas the bevacizumab arm was not.

### 3.3. Comparison of Monthly versus Pro Re Nata (PRN) Regimens

For the comparison of monthly versus PRN regimens, at Year 1, the mean gains in the BCVA (8.82 vs. 6.36 letters; \( p = 0.0018 \)) and the reductions in the CRT (mean \(-146.25 \, \mu \text{m} \) vs. \(-118.68 \, \mu \text{m}; \ p = 0.0194 \)) were significantly higher with the monthly regimens than they were with the PRN regimens (Figure 2A, Figure 2B, respectively), and the IVI number was significantly higher with the monthly regimens (mean 10.6 vs. 7.3; \( p < 0.0001 \)) (Figure 2C).

At Year 2, the IVI number was significantly higher for the monthly regimens versus the PRN regimens (22.9 vs. 13.3; \( p < 0.0001 \)), and the monthly regimens were associated with significantly greater reductions in the CRT (mean \(-185.94 \, \mu \text{m} \) vs. \(-158.28 \, \mu \text{m}; \ p = 0.0332 \)) (Figure 2E,F). Concerning gains in the BCVA (mean 7.89 vs. 6.30 letters; \( p = 0.2973 \)), no significant differences were identified between the monthly and PRN regimens (Figure 2D).

![Figure 2](image-url)  
**Figure 2.** As needed (PRN) versus Monthly regimens. (A–C): Mean change at 1 year, in best corrected visual acuity ((A), blue squares), in CRT ((B), green squares) and in the number of injections ((C), orange squares). (D–F): Mean change at 2 years, in best corrected visual acuity ((D), blue squares), in CRT ((E), green squares) and in the number of injections ((F), orange squares).
3.4. Comparison of Monthly versus Treat-and-Extend (T&E) Regimens

At Year 1, the improvements that were observed in the BCVA (8.82 vs. 7.62 letters; \(p = 0.1305\)) and CRT (mean −146.25 vs. −137.04 µm; \(p = 0.4164\)) were proven to be similar to the observations in the monthly and T&E regimens, whereas the IVI number was significantly lower in the T&E regimens (10.6 vs. 8.2; \(p < 0.0001\)) (Figure 3). At Year 2, no differences in BCVA gains (mean 7.89 vs. 6.38 letters; \(p = 0.0901\)) were revealed between monthly and T&E regimens, but the reduction that was observed in CRT was significantly higher with the monthly than the T&E regimens (−185.94 vs. −136.82 µm; \(p = 0.0003\)), and the IVI number was still significantly lower with the T&E regimen (mean 22.9 vs. 14.6; \(p < 0.0001\)) (Figure 3).

![Figure 3. Treat and Extend (T&E) versus Monthly regimens. (A–C): Mean change at 1 year, in best corrected visual acuity ((A), blue squares), in CRT (B), green squares) and in the number of injections (C, orange squares). (D–F): Mean change at 2 years, in best corrected visual acuity ((D), blue squares), in CRT (E), green squares) and in the number of injections (F, orange squares).]
3.5. Comparison of Pro Re Nata (PRN) Versus Treat-and-Extend (T&E) Regimens

At both Years 1 and 2, the improvements that were observed in the BCVA and CRT, as well as in the IVI number, were similar between the PRN and T&E regimens. The mean gains in the BCVA with PRN regimens versus with T&E regimens at Years 1 and 2 were 6.36 vs. 7.62 letters (p = 0.1075) and 6.30 vs. 6.38 letters (p = 0.9504), respectively. The corresponding mean reductions in CRT were −118.68 vs. −137.04 µm (p = 0.1116) and −158.28 vs. −136.82 µm (p = 0.048), whereas the IVI numbers were 7.3 vs. 8.2 (p = 0.0241) and 13.3 vs. 14.6 (p = 0.3409) at Years 1 and 2, respectively.

3.6. Maintaining Improvements over Time

The monthly, PRN and T&E regimens were all likely to maintain or even improve letter-gaining for BCVA and drying up for CRT between Years 1 and 2 (Table 3). Nevertheless, the mean IVI number differed with each of the regimens over time (10.6 and 22.9 for monthly regimens, 7.3 and 13.3 IVI for PRN regimens and 8.2 and 14.6 for T&E regimens at Years 1 and 2, respectively).

Table 3. Maintenance of changes in BCVA, CRT and IVI numbers over time using monthly, pro re nata and treat-and-extend regimens.

| Change in Best-Corrected Visual Acuity (BCVA) | Regimen | Year | N  | Mean (ETDRS Letters) | 95% CI  | p Value |
|----------------------------------------------|---------|------|----|----------------------|---------|---------|
| Monthly                                      | 1       | 11   | 8.8| [7.8; 10]            |         | 0.3494  |
|                                             | 2       | 4    | 7.9| [6.5; 9.6]           |         |         |
| PRN                                          | 1       | 14   | 6.3| [5.4; 7.5]           |         | 0.9634  |
|                                             | 2       | 5    | 6.3| [4.3; 9.1]           |         |         |
| T&E                                          | 1       | 11   | 7.6| [6.6; 8.8]           |         | 0.0905  |
|                                             | 2       | 9    | 6.4| [5.5; 7.4]           |         |         |

| Change in central retinal thickness (CRT)    | Regimen | Year | N  | Mean  | 95% CI  | p Value |
|----------------------------------------------|---------|------|----|-------|---------|---------|
| Monthly                                      | 1       | 10   | 146.2| [131.1; 163.1] |         | 0.0036  |
|                                             | 2       | 2    | 185.9| [165.1; 209.4] |         |         |
| PRN                                          | 1       | 17   | 118.7| [103.5; 136.1] |         | 0.0005  |
|                                             | 2       | 3    | 158.3| [144.8; 173.0] |         |         |
| T&E                                          | 1       | 9    | 137.0| [122.4; 153.4] |         | 0.9843  |
|                                             | 2       | 8    | 136.8| [122.1; 153.3] |         |         |

| Number of injections                         | Regimen | Year | N  | Mean  | 95% CI  | p Value |
|----------------------------------------------|---------|------|----|-------|---------|---------|
| Monthly                                      | 1       | 6    | 10.6| [10.0; 11.3] |         | <0.0001 |
|                                             | 2       | 2    | 22.9| [22.0; 23.9] |         |         |
| PRN                                          | 1       | 18   | 7.3 | [6.8; 7.9]  |         | <0.0001 |
|                                             | 2       | 2    | 13.3| [11.9; 14.9] |         |         |
| T&E                                          | 1       | 13   | 8.2 | [7.6; 8.8]  |         | <0.0001 |
|                                             | 2       | 9    | 14.6| [12.5; 17.0] |         |         |

Abbreviations: BCVA, best-corrected visual acuity; CRT, central retinal thickness; ETDRS, Early Treatment Diabetic Retinopathy Study; IVI, intravitreal injections; N, number of treatment arms; PRN, pro re nata (as-needed regimen); T&E, treat-and-extend regimen.
3.7. Comparing Aflibercept and Ranibizumab Treat-and-Extend (T&E) Regimens

The mean gains in the BCVA (Figure 4) and reductions in CRT (Figure 4) were similar between aflibercept and ranibizumab T&E regimens at Years 1 and 2, whereas the mean IVI number was significantly lower with aflibercept than ranibizumab at both Years 1 (7.6 and 9.1, respectively) ($p < 0.0001$) and 2 (12.2 and 16.6, respectively) ($p = 0.0011$; Figure 4).

![Figure 4. T&E regimen, Aflibercept versus Ranibizumab. (A–C): Mean change at 1 year, in best corrected visual acuity ((A), blue squares), in CRT ((B), green squares) and in the number of injections ((C), orange squares). (D–F): Mean change at 2 years, in best corrected visual acuity ((D), blue squares), in CRT ((E), green squares) and in the number of injections (F), orange squares.](image-url)
4. Discussion

Anti-VEGF agents are not a curative therapy, but they have become a mainstay and pillar in nAMD management. Indeed, these agents have been proven to slow down disease progression and partially reverse visual impairment [11,66]. Nevertheless, the need for repeated IVI has been a serious burden in AMD management for patients and healthcare systems alike. Hence, alternative administration regimes have been sought, with PRN and T&E regimes the most promising. Under a PRN regimen, the decision to provide an anti-VEGF injection is made at each visit based on the outcomes of the optical coherence tomography measurements. In contrast, when a T&E regimen is applied, the patient undergoes an IVI at each visit, with the between-visit intervals adjusted depending on the disease progression [14]. The primary objective of our meta-analysis was to retrieve further scientific data concerning the visual outcomes and treatment burden with different anti-VEGF agents provided according to either the standard monthly regimen or one of two alternative strategies, PRN or T&E, taking a two-year perspective.

In line with previously published data from the majority of relevant studies, positive outcomes were recorded for all of the anti-VEGF agents and regimens. To summarize our outcome data, at Year 2, both the monthly and T&E regimens resulted in CRT improvements, while the VA outcome improvements were maintained over time with all of the regimens (monthly, PRN, and T&E), and similar improvements in the VA and CRT outcomes were attained with the aflibercept regimens versus the ranibizumab T&E regimens. Hence, our meta-analysis has further confirmed certain previously published observations. Indeed, significantly improved VA and CRT at Years 1 and 2 were previously reported with monthly versus PRN regimens, similar improvements in VA and CRT were reported at Year 1 with both monthly and T&E regimens and similar improvements were observed in the VA and CRT with PRN and T&E regimens, a finding that was revealed in prior meta-analyses [11,12,66]. In addition to previously published data, our analyses revealed that significantly fewer injections were required for PRN and T&E regimens versus monthly regimens at both time points. All in all, these results clearly suggest that T&E is the best alternative strategy that can be recommended for AMD management compared to the monthly and PRN strategies. Considering this T&E regimen, aflibercept generated similar results compared to ranibizumab, but it required a lower IVI number, meaning that this regimen is also able to provide a longer response. In this context, it must be stressed that a recent survey of retinal specialists found that two-thirds of the respondents in the United States (n = 586) and one-third of the respondents in Europe (n = 424) indicated a clear preference for the T&E regimen with respect to managing their treatment-naïve AMD patients (American Society of Retina Specialists’ “2015 global trends in retina” survey results).

The superior efficacy of VA and CRT obtained with monthly versus PRN regimens, as well as the similar efficacy observed with monthly versus T&E regimens in our analysis, are perfectly in line with a recently published Cochrane meta-analysis [67]. These authors revealed that newly diagnosed AMD patients receiving monthly anti-VEGF injections exhibited a slightly better VA at Year 1 versus those receiving PRN injections, whereas no difference in VA was found compared to the T&E regimen. Here, it must be mentioned that, according to the authors, the patients receiving monthly injections actually had a higher IVI number than those receiving injections via PRN or T&E regimens, meaning that patients who were treated monthly were exposed to an increased, although rare, risk of severe undesirable effects such as infections.

An interesting novelty of the current meta-analysis has been its ability to compare the long-term efficacy data of the various anti-VEGF and regimens. For this same purpose, other authors have already focused their research on the outcome data recorded at Years 1 and 2 [11,13,14,50,66]. According to their research, the PRN and T&E regimens displayed VA with decent stability and good control, as well as CRT improvements for up to two years, a finding that is perfectly in line with the monthly standard of care. Moreover, at Year 2, fewer injections were required with both regimens. Here, it must nevertheless be stressed that the PRN regimen appears to be more difficult to handle in real-life settings versus the
T&E regimen due to the required monthly visits. In this context, it must be stressed that PRN regimens have been proven to be effective in prospective randomized studies with carefully selected patients and well-controlled conditions, whereas these regimens were reported to be poorly reproducible in real-life practice [9].

When comparing aflibercept and ranibizumab T&E regimens, their efficacy turned out to be quite similar, whereas this good outcome was achieved with a significantly lower IVI when aflibercept was used at both Years 1 and 2 (7.6 versus 9.1 at Year 1, and 12.2 versus 16.6 at Year 2). In practical terms, this means that aflibercept prolonged the IVI intervals. This outcome is in accordance with the results from a meta-analysis conducted by Ohji et al., which revealed that, at Year 2, aflibercept T&E was associated with six fewer injections on average compared to ranibizumab T&E, providing comparable visual improvements [14]. For clinical practice, this reduced IVI number likely represents a real advantage of aflibercept T&E, especially since anti-VEGF therapy is known to impose a significant additional constraint on patients due treatment-related anxiety and practical problems such as transport burden and common clinic visits [14].

With respect to our analytical methodology, single-means analysis is a new and interesting approach that deserves to be mentioned. This technique enabled us to conduct such a meta-analysis involving large amounts of data to compare three regimens (monthly, PRN and T&E) and two anti-VEGF agents (aflibercept and ranibizumab). Despite the strengths of this statistical methodology, the major limitation was the choice to exclude bevacizumab from the equation. Off-label use of bevacizumab has been discontinued from real-life use. Therefore, our analyses were limited by insufficient data availability. For this reason, several scenarios could not be properly analyzed. Hence, in our literature search, we only came across a few anti-VEGF agent comparisons between monthly versus PRN regimens because most comparisons concerned bevacizumab. It would be interesting to repeat this analysis while including bevacizumab. Likewise, we only identified very few comparisons within the q8w/q12w regimens, given that only brolucizumab has been administered according to the q8w regimen and only very limited data pertaining to the q12w regimen are available. With respect to the q8w regimen, scarcely any data were recorded during Year 2, with several study designs including a regimen change between Years 1 and 2.

We must emphasize several limitations to our report. A major drawback of our meta-analysis, which is rather common, is the failure to obtain data on all patients and from all trials. This may result in an acquisition bias, given that missing studies or patients may not be missing completely at random, resulting in biased outcomes. While meta-analyses represent a powerful tool for the design of future research and to provide evidence for the regulatory process, they may also be controversial, as several conditions are critical to a sound meta-analysis, and small violations of such conditions may lead to misleading results. Another drawback that should be mentioned is that there was a slight discrepancy between the time points at which the Year 2 data were collected.

5. Conclusions

This new meta-analysis revealed superior efficacy, reflected by improvements in VA and CRT with both monthly PRN regimens, but this improved efficacy was achieved with a higher IVI number. On the other hand, the T&E regimens demonstrated similar efficacy to the monthly regimens, but with a reduced IVI number. When comparing the T&E regimens of aflibercept and ranibizumab, aflibercept was associated with a reduced IVI number compared with ranibizumab, but the recorded parameters showed similar efficacy.

Author Contributions: Supervision, F.M.; Validation, F.M., J.-F.K., C.D., V.G., V.S., S.M., M.-N.D., S.B., M.S., P.G., C.C.-G. and L.K.; Writing – original draft, F.M.; Writing—review & editing, F.M., J.-F.K., C.D., V.G., V.S., S.M., M.-N.D., S.B., M.S., P.G., C.C.-G. and L.K. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by BAYER France and The APC was funded by BAYER France.
Istitutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.
Data Availability Statement: To this end, a systematic review of published randomized studies was conducted from the MEDLINE and EMBASE databases and the Cochrane library.

Acknowledgments: Medical writing and editorial assistance was provided by KPL and Galien Health Publishing and was funded by Bayer.

Conflicts of Interest: Frédéric Matonti: Abbvie, Alcon, Allergan, Bausch & Lomb, Bayer, Horus, Novartis, Optos and Théa. Jean-François Korobelnik: Abbvie-Allergan, Bayer, Janssen, Kanghong, Novartis, NovoNordisk, Roche, Thea and Zeiss. Corinne Dot: Abbvie-Allergan, Alcon, Bayer, Horus, Novartis and Théa. Vincent Gualino: Alcon, Allergan, Bayer, Bausch and Lomb, Novartis and Roche. Vincent Soler: Abbvie-Allergan, Alcon, Bayer, Horus, Novartis and Théa. Sarah Mrejen: Bayer and Novartis. Marie-Noëlle Delyfer: Allergan, Bayer, Horama, Horus Pharma, Novartis and Théa. Stéphanie Bailiff: Abbvie-Allergan, Bausch et Lomb, Bayer, Horus Pharma and Novartis. Maté Streho: Abbvie, Alcon, Bayer, Novartis and Quantel-Médical. Pierre Gascon: Bayer and Novartis. L. Kodjikian: Abbvie-Allergan, Alimera, Bayer, Horus, Novartis, Roche and Théa.

References
1. Daien, V.; Finger, R.P.; Talks, J.S.; Mitchell, P.; Wong, T.Y.; Sakamoto, T.; Eldem, B.M.; Korobelnik, J.K. Evolution of treatment paradigms in neovascular age-related macular degeneration: A review of real-world evidence. Br. J. Ophthalmol. 2020, 105, 1475–1479. [CrossRef] [PubMed]
2. Ricci, F.; Bandello, F.; Navarra, P.; Staurenghi, G.; Stumpf, M.; Zarbin, M. Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches. Int. J. Mol. Sci. 2020, 21, 8242. [CrossRef] [PubMed]
3. Age-Related Eye Disease Study Research Group. Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3. Ophthalmology 2000, 107, 2224–2232.
4. Clemons, T.; Milton, R.C.; Klein, R.; Seddon, J. Risk factors for the incidence of advanced age-related macular degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report No. 19. Ophthalmology 2005, 112, 533–539. [PubMed]
5. Brown, D.M.; Kaiser, P.K.; Michels, M.; Soubrane, G.; Heier, J.S.; Kim, R.Y.; Schneider, S.; AS Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 2006, 355, 1432–1444. [CrossRef] [PubMed]
6. Jeger, R.D.; Mieler, W.F.; Miller, J.W. Age-related macular degeneration. N. Engl. J. Med. 2008, 358, 2606–2617. [CrossRef]
7. Chakravarthy, U.; Williams, M. The Royal College of Ophthalmologists guidelines on AMD: Executive summary. Eye 2013, 27, 1429–1431. [CrossRef]
8. Arnold, J.J.; Campain, A.; Barthelmes, D.; Simpson, J.M.; Guymer, R.H.; Hunyor, A.P.; Gillies, M.C.; Fight Retinal Blindness Study Group. Two-year outcomes of treat and extend intravitreal therapy for neovascular age-related macular degeneration. Ophthalmology 2015, 122, 1212–1219.
9. Chong, V. Ranibizumab for the treatment of wet AMD: A summary of real-world studies. Eye 2016, 30, 270–286. [CrossRef]
10. Spaide, R. Ranibizumab according to need: A treatment for age-related macular degeneration. Am. J. Ophthalmol. 2007, 143, 679–680. [CrossRef]
11. Solomon, S.D.; Lindsley, K.; Vedula, S.; Krzystolik, M.G.; Hawkins, B. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst. Rev. 2014, 8, Cd005139. [CrossRef]
12. Sarwar, S.; Clearfield, E.; Soliman, M.K.; Sadiq, M.A.; Baldwin, A.J.; Hanout, M.; Agarwa, A.; Sepah, Y.J.; Do, D.V.; Nguyen, Q.D. Aflibercept for neovascular age-related macular degeneration. Cochrane Database Syst. Rev. 2016, 2, CD011346. [CrossRef] [PubMed]
13. Mozetic, V.; Pacheco, R.L.; Latorraca, C.O.C.; Lee, F.C.Y.O.; Gomes, J.V.B.; Riera, R. What do Cochrane systematic reviews say about interventions for age-related macular degeneration? Sao Paulo Med. J. 2019, 137, 530–542. [CrossRef] [PubMed]
14. Ohji, M.; Takahashi, K.; Okada, A.A.; Kobayashi, M.; Matsuda, Y.; Terano, Y.; ALTAIR Investigators. Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR: A Randomized Controlled Trial. Adv. Ther. 2020, 37, 1173–1187. [CrossRef] [PubMed]
15. Haidich, A.B. Meta-analysis in medical research. Hippokratia 2010, 14, 29–37.
16. Broadhead, G.K.; Hong, T.; Chang, A.A. Treating the untreatable patient: Current options for the management of treatment-resistant neovascular age-related macular degeneration. Acta. Ophthalmol. 2014, 92, 713–723. [CrossRef]
17. Yang, S. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: A comprehensive review. Drug. Des. Dev. Ther. 2016, 10, 1857–1867.
18. Moher, D.; Shamseer, L.; Clarke, M.; Ghersi, D.; Liberati, A.; Petticrew, M.; Shekelle, P.; Stewart, L.A.; PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst. Rev. 2015, 4, 1. [CrossRef] [PubMed]
19. Higgins, J.P.T.; Green, S. Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0 [updated March 2011]. The Cochrane Collaboration: London, UK, 2011.
20. Bro, T.; Derebecka, M.; Jorstad, Ø.K.; Grzybowski, A. Off-label use of bevacizumab for wet age-related macular degeneration in Europe. Graefes Arch. Clin. Exp. Ophthalmol. 2020, 258, 503–511. [CrossRef]
21. Ipique: Pending EC Decision European Medicines Agency (europa.eu). Available online: https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-8-11-november-2021 (accessed on 11 November 2021).
22. Salomon, S.S.; Goldberg, M.F. ETDRS Grading of Diabetic Retinopathy: Still the Gold Standard? Ophthalmic. Res. 2019, 62, 190–195. [CrossRef]
23. Dugel, P.U.; Koh, A.; Ogura, Y.; Jaffe, G.J.; Schmidt-Erfurth, U.; Brown, D.M.; Holz, F.G.; Hawk and Harrier Investigators. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology 2020, 27, 72–84. [CrossRef]
24. Kertes, P.J.; Galic, I.J.; Greve, M.; Williams, G.; Baker, J.; Lahaie, M.; Sheidow, T. Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease: A Randomized Clinical Trial. JAMA Ophthalmol. 2020, 138, 244–250. [CrossRef]
25. Staurenghi, G.; Garweg, J.G.; Gerendas, B.S.; Macfadden, W.; Gekkiev, B.; Margaron, P.; Dunger-Baldauf, C.; Kolar, P. Functional versus functional and anatomical criteria-guided ranibizumab treatment in patients with neovascular age-related macular degeneration-results from the randomized, phase IIIb OCTAVE study. BMC Ophthalmol. 2020, 20, 18. [CrossRef] [PubMed]
26. Gillies, M.C.; Hunyor, A.P.; Arnold, J.J.; Guymer, R.H.; Wolf, S.; Ng, P.; Pecheur, F.L.; McAllister, I.L. Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration. A Randomized Clinical Trial. JAMA Ophthalmol. 2019, 137, 372–379. [CrossRef] [PubMed]
27. Guymer, R.H.; Markey, C.M.; McAllister, I.L.; Gillies, M.C.; Hunyor, A.P.; Arnold, J.J.; Fluid Investigators. Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen: FLUID Study 24-Month Results. Ophthalmology 2019, 126, 723–734. [CrossRef] [PubMed]
28. Kertes, P.G.; Galic, I.J.; Greve, M.; Williams, R.G.; Rampakakis, E.; Scarino, A.; Sheidow, T. Canadian Treat-and-Extend Analysis Trial with Ranibizumab in Patients with Neovascular Age-Related Macular Disease: One-Year Results of the Randomized Canadian Treat-and-Extend Analysis Trial with Ranibizumab Study. Ophthalmology 2019, 126, 841–848. [CrossRef]
29. Mitchell, P.; Souied, E.H.; Midena, E.; Holz, F.G.; Hykin, P.G.; Wolf, S.; Allmeier, H. Efficacy of Intravitreal Aflibercept Administered using Treat-and-Extend Regimen over 2 Years in Patients with Neovascular Age-Related Macular Degeneration: 1-Year ARIES Results. Investig. Ophthalm. Vis. Sci. 2019, 60, 117. [CrossRef]
30. Nunes, R.P.; Hirai, F.E.; Barroso, L.F.; Badaro, R.; Novais, E.; Rodrigues, E.B.; Maia, M.; Magalhaes, O.; Farah, M.E. Effectiveness of monthly and fortnightly anti-VEGF treatments for age-related macular degeneration. Arq. Bras. Oftalmol. 2019, 82, 225–232. [CrossRef]
31. Semeraro, F.; Gambicordi, E.; Cancarin, A.; Morescalchi, F.; Costagliola, C.; Russo, A. Treatment of exudative age-related macular degeneration with aflibercept combined with pranoprofen eye drops or nutraceutical support with omega-3: A randomized trial. Br. J. Clin. Pharmacol. 2019, 85, 908–913. [CrossRef]
32. Wykoff, C.C.; Ou, W.C.; Croft, D.E.; Payne, J.F.; Brown, D.M.; Clark, W.L.; Abdelfattah, N.S.; Sadda, S.R. Neovascular age-related macular degeneration management in the third year: Final results from the TREX-AMD randomised trial. Br. J. Ophthalmol. 2018, 102, 460–464. [CrossRef]
33. Russo, A.; Scaroni, N.; Gambicorti, E.; Turano, R.; Morescalchi, F.; Costagliola, C.; Semeraro, F. Combination of ranibizumab and indomethacin for neovascular age-related macular degeneration: Randomized controlled trial. Clin. Ophthalmol. 2018, 12, 587–591. [CrossRef]
34. Silva, R.; Berta, A.; Larsen, M.; Macfadden, W.; Feller, C.; Mones, J.; TREND Study Group. Treat-and-Extend versus Monthy Regimen in Neovascular Age-Related Macular Degeneration: Results with Ranibizumab from the TREND Study. Ophthalmology 2018, 125, 57–65. [CrossRef] [PubMed]
35. Dugel, P.U.; Jaffe, G.J.; Sallstig, P.; Warburton, J.; Weichselberger, A.; Wieland, M.; Singerman, L. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial. Ophthalmology 2017, 124, 1296–1304. [CrossRef] [PubMed]
36. Feltgen, N.; Bertelmann, T.; Bretag, M.; Pfeiffer, S.; Hilgers, R.; Callizo, J.; Goldammer, L.; Bemme, S.; Hoerauf, H. Efficacy and safety of a fixed bimonthly ranibizumab treatment regimen in eyes with neovascular age-related macular degeneration: Results from the RABIMO trial. Graefes Arch. Clin. Exp. Ophthalmol. 2017, 255, 923–934. [CrossRef] [PubMed]
37. Gallemore, R.P.; Wallsh, J.; Hudson, H.L.; Ho, A.C.; Chace, R.; Pearlman, J. Combination verteporfin photodynamic therapy ranibizumab-dexamethasone in choroidal neovascularization due to age-related macular degeneration: Results of a phase II randomized trial. Clin. Ophthalmol. 2017, 11, 223–231. [CrossRef]
38. Li, X.; Chen, Y.; Zhang, J.; Xu, X.; Zhang, F.; Cheung, C.M.G.; Yu, R.; Kazmi, H.; Sowade, O.; Zeitz, O.; et al. Intravitreal Aflibercept Versus Photodynamic Therapy in Chinese Patients with Neovascular Age-Related Macular Degeneration:Outcomes of the SIGHT Study. J. Ocul. Pharm. 2017, 33, 435–444. [CrossRef]
39. Mori, R.; Tanaka, K.; Haruyama, M.; Kawamura, A.; Furuya, K.; Yuzawa, M. Comparison of pro re nata versus Bimonthly Injection of Intravitreal Aflibercept for Typical Neovascular Age-Related Macular Degeneration. Ophthalmology 2017, 238, 17–22. [CrossRef]
58. Martin, D.F.; Maguire, M.G.; Fine, S.L.; Ying, G.S.; Jaffe, G.F.; Grunwald, J.E.; Toth, C.; Redford, M.; Ferris, F.L., 3rd. Ranibizumab  
52. Heier, J.S.; Brown, D.M.; Chong, V.; Korobelnik, J.F.; Kaiser, P.K.; Nguyen, Q.; Schmidt-Erfurt, U.; View VS Groups. Intravitreal  
54. Larsen, M.; Schmidt-Erfurth, U.; Delcassì, L.; Romano, M.R.; Rinaldi, M.; Chiosi, F.; Costagliola, C. Treatment of Exudative Age-Related  
50. Krebs, I.; Schmetterer, L.; Boltz, A.; Told, R.; Vecsei-Marlovits, V.; Bodenstorfer, J.; Glittenberg, C.; Ansari-Shahrezaei, S.; Ristl, R.; Binder, S. Comparison of  
49. Krebs, I.; Vecsei Marlovits, V.; Bodenstorfer, J.; Glittenberg, C.; Ansari Shahrezaei, S.; Ristl, R.; Binder, S. Comparison of Ranibizumab monotherapy versus combination of Ranibizumab with photodynamic therapy with neovascular age-related macular degeneration. Acta Ophthalmol. 2013, 91, 178–183. [CrossRef] [PubMed]  
48. Kodjikian, L.; Souried, E.H.; Mimoun, G.; Mauget-Faysse, M.; Behar-Cohen, F.; Decullier, E.; Huot, L.; Aulagner, G.; GS Group. Ranibizumab versus Bevacizumab for Neovascular Age-Related Macular Degeneration: Results from the GEFA Noninferiority Randomized Trial. Ophthalmology 2013, 120, 2300–2309. [CrossRef] [PubMed]  
47. Dugel, P.U.; Bebchuk, J.D.; Nau, J.; Reichel, E.; Singer, M.; Barak, A.; Binder, S.; Jackson, T.L.; CS Group. Epimacular brachytherapy for neovascular age-related macular degeneration: A randomized, controlled trial (CABERNET). Ophthalmology 2013, 120, 317–327. [CrossRef] [PubMed]  
46. Ho, A.C.; Busbee, B.G.; Regillo, C.D.; Wieland, M.R.; Van Everen, S.A.; Li, Z.; Rubio, R.; Lai, P.; HS Group. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab intravitreal injections in the treatment of neovascular age-related macular degeneration. Ophthalmology 2014, 121, 2181–2192. [CrossRef]  
45. Williams, P.D.; Callanan, D.; Solley, W.; Avery, R.; Pieramici, D.J.; Aaberg, T. A prospective pilot study comparing combined intravitreal ranibizumab and half-fluence photodynamic therapy with ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration. Br. J. Ophthalmol. 2013, 97, 266–271. [CrossRef]  
44. Semeraro, F.; Russo, A.; Delcassì, L.; Romano, M.R.; Rinaldi, M.; Chiosi, F.; Costagliola, C. Treatment of Exudative Age-Related Macular Degeneration with Ranibizumab Combined with Ketorolac Eyedrops or Photodynamic Therapy. Retina 2015, 35, 1547–1554. [CrossRef] [PubMed]  
43. Eldem, B.M.; Muftuoglu, G.; Topbas, S.; Cakir, M.; Kadayifcilar, S.; Ozmert, E.; Bahcecioglu, H.; Sahin, F.; Sevgi, S.; Salute Study Group. Comparison of ranibizumab and bevacizumab for choroidal neovascularization secondary to AMD. Acta Ophthalmol. 2015, 93, 458–464. [CrossRef]  
42. Berg, K.; Pedersen, T.; Sandvik, L.; Bragadottir, R. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol: Two-Year Results. Ophthalmology 2016, 123, 51–59. [CrossRef]  
41. Berg, K.; Hadzalic, E.; Gjertsen, I.; Forsaa, V.; Berger, L.H.; Kinge, B.; Bragadottir, R. Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration According to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol. Ophthalmology 2015, 122, 146–152. [CrossRef]  
40. Weingessel, B.; Mihaltz, K.; Vecsei-Marlovits, P.V. Predictors of 1-year visual outcome in OCT analysis comparing ranibizumab monotherapy versus combination therapy with PDT in exsudative age-related macular degeneration. Wien Klin Wochenschr. 2016, 128, 560–565. [CrossRef]
60. Vallance, J.H.; Johnson, B.; Majid, M.A.; Banerjee, S.; Mandal, K.; Bailey, C.C. A randomised prospective double-masked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab vs intravitreal ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration. *Eye* 2010, 24, 1561–1567. [CrossRef]

61. Heier, J.S.; Boyer, D.; Nguyen, Q.D.; Marcus, D.; Roth, D.B.; Yancopoulos, G.; Brown, D.M.; for the CLEAR-IT 2 Investigators. The 1-year Results of CLEAR-IT 2, a Phase 2 Study of Vascular Endothelial Growth Factor Trap-Eye Dosed As-needed after 12-week Fixed Dosing. *Ophthalmology* 2011, 118, 1098–1106. [CrossRef]

62. Kunimoto, D.; Yoon, Y.H.; Wykoff, C.C.; Chang, A.; Khurana, R.N.; Maturi, R.K.; Hashad, Y.; on behalf of the CEDAR and SEQUOIA Study Groups. Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration: 52-Week Results of Phase 3 Randomized Controlled Study. *Ophthalmology* 2020, 127, 1331–1344. [CrossRef]

63. Khurana, R.N.; Kunimoto, D.; Yoon, Y.H.; Wykoff, C.C.; Chang, A.; Maturi, R.K.; Hashad, Y.; CEDAR and SEQUOIA Study Groups. Two-Year Results of the Phase 3 Randomized Controlled Study of Abicipar in Neovascular Age-Related Macular Degeneration. *Ophthalmology* 2021, 128, 1027–1038. [CrossRef]

64. The CATT Research Group. Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration. *N. Engl. J. Med.* 2011, 364, 1897–1908. [CrossRef] [PubMed]

65. Taipale, C.; Lindholm, J.M.; Laine, I.; Tuuminen, R. Comparison of two different treat-and-extend protocols with aflibercept in wet age-related macular degeneration. *Acta. Ophthalmol.* 2020, 98, 267–273. [CrossRef] [PubMed]

66. Li, X.; Zhu, A.; Egger, A.; Song, Y.; Zhang, J.; Dong, F.; Xu, X. Ranibizumab 0.5 mg for Neovascular Age-Related Macular Degeneration: Monthly versus as Needed Dosing in the DRAGON Study. *Ophthalmologica* 2016, 236, 20–21.

67. Li, E.; Donati, S.; Lindsley, K.B.; Krzystolik, M.G.; Virgili, G. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration. *Cochrane. Database. Syst. Rev.* 2020, 5, CD012208. [PubMed]